Volume | 979,115 |
|
|||||
News | - | ||||||
Day High | 1.27 | Low High |
|||||
Day Low | 1.205 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Aclaris Therapeutics Inc | ACRS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.21 | 1.205 | 1.27 | 1.26 | 1.21 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
5,487 | 979,115 | US$ 1.24 | US$ 1,213,428 | - | 0.5902 - 11.12 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:01:54 | priorref | 1,972 | US$ 1.26 | USD |
Aclaris Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
89.37M | 70.93M | - | 31.25M | -88.48M | -1.25 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aclaris Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACRS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.21 | 1.27 | 1.14 | 1.19 | 1,019,276 | 0.05 | 4.13% |
1 Month | 1.22 | 1.30 | 1.14 | 1.21 | 744,720 | 0.04 | 3.28% |
3 Months | 1.12 | 1.51 | 1.05 | 1.21 | 1,106,657 | 0.14 | 12.50% |
6 Months | 5.00 | 5.705 | 0.5902 | 1.02 | 3,085,452 | -3.74 | -74.80% |
1 Year | 8.88 | 11.12 | 0.5902 | 2.42 | 1,916,598 | -7.62 | -85.81% |
3 Years | 23.67 | 25.00 | 0.5902 | 6.72 | 1,021,798 | -22.41 | -94.68% |
5 Years | 6.32 | 30.375 | 0.5902 | 7.52 | 1,038,886 | -5.06 | -80.06% |
Aclaris Therapeutics Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. |